Amendment: SEC Form SC 13G/A filed by Praxis Precision Medicines Inc.
$PRAX
Biotechnology: Pharmaceutical Preparations
Health Care
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/10/2026 | $815.00 | Strong Buy | Raymond James |
| 2/24/2026 | $500.00 | Outperform | Wolfe Research |
| 2/2/2026 | $282.00 | Equal Weight | Wells Fargo |
| 12/15/2025 | $250.00 → $750.00 | Outperform | Oppenheimer |
| 11/19/2025 | $424.00 | Buy | BTIG Research |
| 6/2/2025 | $97.00 | Outperform | Oppenheimer |
| 5/7/2025 | $80.00 | Buy | Chardan Capital Markets |
| 3/3/2025 | $120.00 → $105.00 | Buy | H.C. Wainwright |
BOSTON, June 02, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that on June 1, 2026, the Compensation Committee of Praxis' Board of Directors granted restricted stock unit awards covering an aggregate of 2,754 shares of its common stock to thirteen new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock unit awards were granted as inducements material to the employees' entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4). Th
POWER1 Study in highly refractory patients with focal onset seizures did not meet its primary success measure Secondary measure, the 50% response rate, was met and seizure reduction during the second half of the study on higher dose (30 mg) was more pronounced Vormatrigine was generally well-tolerated; adverse event-related discontinuations were less than 10% Approximately 90% of patients from the vormatrigine arm transitioned to and remain in the open label extension (OLE) study Praxis is pausing enrollment in the POWER2 study to reassess the vormatrigine program and determine potential modifications BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ
FDA accepted the new drug application (NDA) for ulixacaltamide in Essential Tremor with a PDUFA target action date of January 29, 2027, and the NDA for relutrigine, with priority review, in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) with a PDUFA target action date of September 27, 2026 EMBRAVE Part A study results showed elsunersen treatment led to a 77% placebo-adjusted reduction in monthly seizures and demonstrated disease-modifying improvements in patients with early-seizure onset SCN2A-DEE Topline results from the POWER1 study of vormatrigine in focal onset seizures expected in Q2 2026 Recruiting completed for relutrigine EMERALD study in broad DEEs, with top
Raymond James initiated coverage of Praxis Precision Medicines with a rating of Strong Buy and set a new price target of $815.00
Wolfe Research initiated coverage of Praxis Precision Medicines with a rating of Outperform and set a new price target of $500.00
Wells Fargo initiated coverage of Praxis Precision Medicines with a rating of Equal Weight and set a new price target of $282.00
4 - Praxis Precision Medicines, Inc. (0001689548) (Issuer)
4 - Praxis Precision Medicines, Inc. (0001689548) (Issuer)
4 - Praxis Precision Medicines, Inc. (0001689548) (Issuer)
4 - Praxis Precision Medicines, Inc. (0001689548) (Issuer)
8-K - Praxis Precision Medicines, Inc. (0001689548) (Filer)
SCHEDULE 13G - Praxis Precision Medicines, Inc. (0001689548) (Subject)
SCHEDULE 13G/A - Praxis Precision Medicines, Inc. (0001689548) (Subject)
BOSTON, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced the appointment of world-renowned neurologist and epilepsy authority Dr. Orrin Devinsky, M.D., as Head of Clinical Strategy, a newly created leadership role. Dr. Devinsky is widely regarded as one of the most influential physician-scientists of his generation in modern epilepsy and clinical neuroscience. Over a career spanning more than four decades, he has shaped the development of multiple transformative therapies, built enduring global research initiatives, and helped define t
BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation–inhibition imbalance, today announced the appointment of Jeffrey B. Kindler and Stuart Arbuckle to its board of directors, and the promotions of Megan Sniecinski to Chief Operating Officer and Dr. Steven Petrou to President of Research & Development. "These leadership decisions reflect a deliberate evolution of Praxis as we enter a phase driven by commercial launch planning and execution readiness, late-stage developm
PRAX-944 Phase 2b Essential1 Study topline results expected in 4Q22; primary endpoint updated to efficacy PRAX-562 Phase 1 study completed, confirming biomarker change and potential for wide therapeutic window Cash and investments of $165.4 million as of June 30, 2022 supports runway into 1Q24 BOSTON, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today provided a corporate update and reported financial results for the second quarter of 2022
BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced it will report its financial results for the first quarter ended March 31, 2026, and provide a corporate update before the financial markets open on Thursday, May 7, 2026. The Company will host a conference call and a live webcast to review the first quarter financial results and provide a corporate update on Thursday, May 7, 2026, at 8:30 am ET, which can be accessed by visiting this registration link. The live webcast will also be available on the Events & Presentations page of
BOSTON, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced it will report its financial results for the fourth quarter and full year ended December 31, 2025, and provide a corporate update before the financial markets open on Thursday, February 19, 2026. The Company will host a conference call and a live webcast to review the fourth quarter financial results and provide a corporate update on Thursday, February 19, 2026, at 8:00 am ET, which can be accessed by visiting this registration link. The live webcast will also be available on the
RADIANT study with vormatrigine in focal onset seizure (FOS) patients over eight weeks demonstrated 56.3% median reduction in seizure frequency from baseline, with 22% at 100% seizure reduction in last 28 days Initiated two registrational studies for Developmental and Epileptic Encephalopathies (DEEs) programs: EMERALD for broad DEEs with relutrigine and EMBRAVE3 for SCN2A Gain-of-Function (GoF) with elsunersen Relutrigine granted U.S. FDA Breakthrough Therapy Designation for the treatment of seizures associated with SCN2A and SCN8A DEEs, enabling expedited development Cash and investments of approximately $447 million as of June 30, 2025 maintains runway into 2028 Praxi
SC 13G/A - Praxis Precision Medicines, Inc. (0001689548) (Subject)
SC 13G/A - Praxis Precision Medicines, Inc. (0001689548) (Subject)
SC 13G/A - Praxis Precision Medicines, Inc. (0001689548) (Subject)